3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Plasma cell
1
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Interventions
pembrolizumab
93
Nivolumab
61
Docetaxel
55
Cyclophosphamide
49
enzalutamide
44
Magnetic Resonance Spectroscopy
33
Ipilimumab
33
Gemcitabine
32
Abiraterone Acetate
30
Prednisone
29
fludarabine
28
Everolimus
27
Paclitaxel
25
Cisplatin
24
Radiotherapy
23
Carboplatin
23
Sunitinib
22
cabozantinib
21
atezolizumab
20
Radiosurgery
20
Specimen Handling
19
Sorafenib
18
Bevacizumab
18
pazopanib
17
bicalutamide
17
abiraterone
17
Biopsy
15
temsirolimus
14
darolutamide
14
apalutamide
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
lirilumab
×
Genitourinary
×
Clear all
NCT03532451
2024-09-19
PrE0807
PrECOG, LLC.
Phase 1
Completed
43 enrolled
15 charts